BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product

Stock Information for BioSyent Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioSyent Inc.

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
BioSyent to Present at LD Micro New York Investor Conference
BioSyent Announces Grant of Restricted Share Units
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
BioSyent Named to 2024 TSX Venture 50

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.